银黄口服制剂治疗急性上呼吸道感染的系统评价与Meta分析  

A Systematic Review and Meta-analysis of Yinhuang Oral Preparation for Acute Upper Respiratory Infection

作　　者：冯群 关永霞 范建伟 程国良 张贵民 FENG Qun;GUAN Yongxia;FAN Jianwei;CHENG Guoliang;ZHANG Guimin(Lunan Hope Pharmaceutical Co.,Ltd.,Linyi 276006,China;State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine,Linyi 276006,China;Lunan Pharmaceutical Group Co.,Ltd.,Linyi 276006,China)

机构地区：[1]鲁南厚普制药有限公司,临沂276006 [2]中药制药共性技术国家重点实验室,临沂276006 [3]鲁南制药集团股份有限公司,临沂276006

出　　处：《世界中医药》2022年第6期814-819,共6页World Chinese Medicine

基　　金：山东省重点研发计划项目(2017CXGC1308)。

摘　　要：目的:系统评价银黄口服制剂治疗急性上呼吸道感染的疗效和安全性,为临床急性上呼吸道感染的治疗提供循证医学证据。方法:检索中国期刊全文数据库(CJFD),中国学术期刊数据库(CSPD),中文科技期刊数据库(CCD)、中国生物医学文献数据库(CBM)、EmBase、PubMed、Cochrane Library等数据库,收集银黄口服制剂治疗急性上呼吸道感染的随机对照临床试验文献。对纳入文献进行质量评价和资料提取,数据采用Review Manager 5.3软件进行Meta分析,对于不能合并的研究采用描述性分析。结果:共纳入10项研究,包含2165例患者。Meta分析结果显示,与对照组比较,应用银黄口服制剂治疗急性上呼吸道感染,可提高治疗总有效率(RR=1.22,95%CI为1.10~1.34,P<0.0001)、改善咽痛症状(RR=1.44,95%CI为0.76~2.72,P=0.27)、缩短咳嗽、发热、咽痛的持续时间(MD=-0.83,95%CI为-1.30~-0.36,P=0.0005;MD=-1.40,95%CI为-2.07~-0.72,P<0.0001;MD=-0.94,95%CI为-1.07~-0.81,P<0.00001);2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:银黄口服制剂治疗急性上呼吸道感染具有显著疗效,且并未增加不良反应发生率,但其疗效尚需更多高质量的研究予以支持。Objective:To systematically evaluate the clinical efficacy and safety of Yinhuang oral preparations in the treatment of acute upper respiratory infection and provide evidence-based references for clinical treatment of acute upper respiratory infection.Methods:The databases,such as CJFD,CSPD,CCD,CBM,Embase,PubMed,and Cochrane Library,were systematically searched for randomized controlled trials(RCTs)on Yinhuang oral preparations in treating acute upper respiratory infarction,and the included RCTs underwent quality evaluation and data extraction.Review Manager 5.3 was used for Meta-analysis,and descriptive analysis was carried out for RCTs that could not be combined.Results:Ten RCTs were included,with 2165 involved.The Meta-analysis showed that compared with the conditions in the control group,Yinhuang oral preparations could improve clinical total effective rate[RR=1.22,95%CI(1.10 to 1.34),P<0.0001],relieve sore throat[RR=1.44,95%CI(0.76 to 2.72),P=0.27],and shorten duration time of cough,fever,and sore throat[MD=-0.83,95%CI(-1.30 to-0.36),P=0.0005;MD=-1.40,95%CI(-2.07 to-0.72),P<0.0001;MD=-0.94,95%CI(-1.07 to-0.81),P<0.00001].There was no statistical difference in the adverse events between the two groups.Conclusion:Yinhuang oral preparations had a significant curative effect in the treatment of acute upper respiratory infection without increasing the incidence of adverse events.The efficacy,however,needs to be confirmed by more high-quality trials.

关 键 词：急性上呼吸道感染 咽炎 银黄颗粒 银黄口服液 随机对照试验 系统评价 META分析 安全性 

分 类 号：R259[医药卫生—中西医结合]